APA (7th ed.) Citation

L, F., S, G., W, K., A, B., A, L., F, M., . . . SA, G. (2026). Real-world overall survival comparison between first-line Bruton tyrosine kinase inhibitors in treating chronic lymphocytic leukemia/small lymphocytic lymphoma: An analysis of Veterans Health Administration data. Journal of managed care & specialty pharmacy, 32(2), 186. https://doi.org/10.18553/jmcp.2025.25169

Chicago Style (17th ed.) Citation

L, Fitzgerald, et al. "Real-world Overall Survival Comparison Between First-line Bruton Tyrosine Kinase Inhibitors in Treating Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma: An Analysis of Veterans Health Administration Data." Journal of Managed Care & Specialty Pharmacy 32, no. 2 (2026): 186. https://doi.org/10.18553/jmcp.2025.25169.

MLA (9th ed.) Citation

L, Fitzgerald, et al. "Real-world Overall Survival Comparison Between First-line Bruton Tyrosine Kinase Inhibitors in Treating Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma: An Analysis of Veterans Health Administration Data." Journal of Managed Care & Specialty Pharmacy, vol. 32, no. 2, 2026, p. 186, https://doi.org/10.18553/jmcp.2025.25169.